What are the mechanism of action, approved indications, contraindications, and side effects of remibrutinib?

Remibrutinib: Mechanism, Indications, Contraindications, and Side Effects

Mechanism of Action

Remibrutinib is an oral, highly selective covalent inhibitor of Bruton's tyrosine kinase (BTK) that blocks mast cell and basophil degranulation, thereby preventing the release of histamine and other proinflammatory mediators. 1

BTK is an intracellular signaling protein expressed in mast cells, basophils, B cells, macrophages, and platelets. It functions downstream of:

• Fc epsilon receptor-1 (FcεR1)
• Fc gamma receptors (FcγR)
• B cell antigen receptor (BCR)

By inhibiting BTK, remibrutinib interrupts the inflammatory cascade at its source, providing upstream control of disease activity. The drug also inhibits related kinases TEC (tec protein tyrosine kinase) and BMX (BMX non-receptor tyrosine kinase). 1

Approved Indications

Remibrutinib is FDA-approved for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1-antihistamine treatment. 2, 3

This represents the first targeted oral therapy for CSU, approved on September 30,2025. The drug has subsequently received approval in China and is under regulatory review in the EU and Japan. 3

The approval was based on the Phase 3 REMIX-1 and REMIX-2 trials, which demonstrated:

• Rapid and sustained improvements in Urticaria Activity Score (UAS7)
• Approximately one-third of patients achieved complete symptom resolution by week 12
• Sustained efficacy maintained through 52 weeks 4, 5

Contraindications and Precautions

Hepatic Impairment

Avoid use of remibrutinib in patients with any degree of hepatic impairment (Child-Pugh Class A, B, or C), as drug exposure is significantly increased in these patients. 1

Drug Interactions

Strong CYP3A4 inhibitors and inducers:

• Remibrutinib is primarily metabolized by CYP3A4
• Avoid concomitant use with strong CYP3A4 inhibitors or inducers 1

P-glycoprotein (P-gp) substrates:

• Remibrutinib inhibits P-gp and increases exposure of P-gp substrates (e.g., digoxin)
• Monitor for adverse reactions related to P-gp substrates 1

Antithrombotic agents:

• Consider risks and benefits carefully when co-administering with anticoagulants
• Anticoagulants were not allowed in clinical trials
• Antiplatelet agents (aspirin ≤100 mg daily or clopidogrel ≤75 mg daily) were permitted in studies 1

Special Populations

Pregnancy (Category: Insufficient data):

• Animal studies showed external malformations in rabbits at 141-times human exposure
• No adverse effects in rats at 126-times human exposure
• Pregnancy exposure registry available: 1-888-669-6682 1

Lactation:

• No data on presence in human or animal milk
• Consider benefits of breastfeeding versus maternal need for treatment 1

Pediatric use:

• Safety and effectiveness not established in pediatric patients 1

Geriatric use:

• No dose adjustment needed; no observed differences in safety or efficacy in patients 65-85 years 1

Side Effects

Common Adverse Events

The safety profile is generally favorable, with most adverse events being mild to moderate. 4, 5

Most frequent adverse events by system organ class:

• Infections: 30.9% (most common category)
• Skin and subcutaneous tissue disorders: 26.8%
• Gastrointestinal disorders: 16.5% 5

Key Safety Findings

No clinically significant effects on:

• QTc prolongation (at concentrations 9-times the therapeutic level) 1
• Blood pressure (assessed by 24-hour ambulatory monitoring) 1

Long-term safety:

• Exposure-adjusted incidence rates of adverse events, serious adverse events, and discontinuations remained stable through 52 weeks
• No dose-dependent pattern of adverse events observed 4, 6

Monitoring requirements:

• No routine laboratory monitoring needed 2

Maternal/Fetal Toxicity

At high doses in animal studies (194-times human exposure):

• Maternal moribundity and clinical toxicity
• Slightly longer gestation lengths
• Higher stillborn rates and smaller litter sizes at birth
• No effects on surviving offspring developing into adulthood 1

Dosing and Administration

Recommended dose: 25 mg orally twice daily 1, 4

Pharmacokinetic properties:

• Tmax: 1 hour (median)
• Half-life: 1-2 hours
• Can be taken with or without food (no clinically significant food effect)
• Dose-proportional exposure between 0.4 to 4 times the recommended dose 1